HCPCS | Generic Name | Brand Name (Ascending) | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | venetoclax | Venclexta | 10 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | venetoclax | Venclexta | 50 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | venetoclax | Venclexta | 100 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | Abemaciclib | Verzenio | 50 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Abemaciclib | Verzenio | 100 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Abemaciclib | Verzenio | 150 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Abemaciclib | Verzenio | 200 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | tretinoin | Vesanoid | 10 mg | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Yes | 1995 | In Use | |||
J9219 | Leuprolide Acetate Implant | Viadur | 65 mg | Hormonal Therapy | GnRH Agonist | No | 2000 | Jan. 1, 2016 | In Use | |||
J9025 | Azacitidine | Vidaza | 1 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2004 | Jan. 1, 2006 | In Use | ||
NA | Vismodegib | Vismodegib | 150 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2012 | In Use | |||
NA | Uridine Triacetate | Vistogard | 10 g | Ancillary Therapy | Chemoprotective | Antidote | Yes | 2015 | In Use | |||
NA | Larotrectinib | Vitrakvi | 25mg, 100mg 20mg/ml | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Yes | 2018 | In Use | |||
J9056 | Bendamustine | Vivimusta | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | July 11, 2023 | In Use | ||
NA | Dacomitinib | Vizimpro | 15mg, 30mg, 45mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2018 | In Use | |||
Pacritinib | Vonjo | 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Yes | 2022 | In Use | ||||
C9293 | Glucarpidase | Voraxaze | 10 units | Ancillary Therapy | Chemoprotective | Antidote | No | 2012 | Jan. 1, 2012 | In Use | ||
NA | Pazopanib | Votrient | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT, Lck, FMS | Yes | 2009 | In Use | |||
C9024 | (Daunorubicin AND Cytarabine) Liposome | Vyxeos | 1mg/2.27mg | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | No | 2017 | In Use | |||
BA | Belzutifan | Welireg | 40mg | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Yes | 2021 | In Use | |||
NA | Crizotinib | Xalkori | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
NA | Crizotinib | Xalkori | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
J8612 | Methotrexate (xatmep) | Xatmep | 2.5mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 2017 | June 10, 2024 | In Use | ||
J8520 | Capecitabine | Xeloda | 150 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 1998 | Jan. 1, 2000 | In Use | ||
J8521 | Capecitabine | Xeloda | 500 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 1998 | Jan. 1, 2000 | In Use |
Found 716 results in 3 milliseconds — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.